Esperion's Bempedoic Acid Receives Strong Endorsement in ACC/AHA Dyslipidemia Guideline.

Esperion's bempedoic acid has received multiple Class 1 recommendations in the 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia. It is endorsed for patients with statin intolerance, severe hypercholesterolemia, and primary and secondary prevention. Bempedoic acid is positioned equally with PCSK9 mAb and ezetimibe for high-risk primary prevention and clinical ASCVD not at very high-risk patients. The guideline emphasizes the importance of earlier, aggressive combination therapy and statin intolerance as a significant clinical challenge.